Search Results

August 2024 August 2024 CSL held a virtual investor briefing On the same day as announcing June 2025 following the release of its full-year full year results, CSL announced the results, with the briefing materials appointment of Ms Elaine Sorg to released to the ASX on 13 August 2024.

On-market purchases under the plan were made twice yearly, following the announcement of CSL's half and full year results Additional shares may be purchased by NEDs on-market at prevailing share prices in accordance with CSL's Securities Dealing Policy Post-Employment Benefits Superannuation contributions are made in accordance with legislation and are included in the reported base fee, and are not additional to the base fee.

On 17 August 2016, CSL announced its full year results for Esterase Inhibitor Subcutaneous (Human)) had been (b) of this Directors' Report.

Shares are purchased by NEDs on-market consideration of eight Global Biopharmaceutical companies of at prevailing share prices, twice yearly, after the announcement of CSL's half and full year results.

CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.

Unvested Rights represent the tranches that will vest on 22 August 2025, following the release of full year financial results.

46 Unvested Rights represent Tranche 2 of the 2023 grant that will vest on 21 August 2023, following the release of full year financial results.

Rights are allocated in two tranches and vesting occurs following the disclosure of half year and full year financial results following the grant of Rights.

We look forward to sharing the full results of our phase 3 study in the coming months.

The baseline year has therefore been restated to 2024/2025, ensuring that future emissions reductions are measured against a consistent and comprehensive baseline that reflects our full operational impact.